Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CoronaTcP; naNo-COVID; PepGNP-COVID19; PepGNP-SARSCoV2; T-Cell Priming COVID-19 vaccine

Latest Information Update: 05 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emergex Vaccines
  • Class COVID-19 vaccines; Peptide vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I COVID 2019 infections

Most Recent Events

  • 03 Jan 2024 Philippines Food & Drug Administration approves IND application for phase I/II trial for PepGNP SARSCoV2 in COVID-2019 infections
  • 17 Nov 2023 Emergex Vaccines plans a phase II trial for COVID-2019 infections (Prevention) (Intradermal, Injection), in H1 2024
  • 05 Oct 2023 Emergex enters into collaboration agreement with Vaccine Industrial Company advancing Emergex’s novel T cell-priming immune candidates against infectious diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top